We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Macy's (M) Beats on Q3 Earnings & Sales, Updates Outlook
Read MoreHide Full Article
Macy’s, Inc. (M - Free Report) delivered the sixth straight quarter of positive earnings surprise, when it reported third-quarter fiscal 2018 results. Total sales also came ahead of the consensus mark after missing the same in the preceding quarter. Better-than-expected results prompted management to lift earnings view.
The company highlighted that impressive performance across Macy’s, Bloomingdale’s and Bluemercury brands boosted results. Management hinted that its Growth50 stores initiative is aiding its brick-and-mortar performance. This along with double-digit growth in the digital business bode well. Notably, this Zacks Rank #2 (Buy) stock has rallied 42% year to date, compared with the industry's gain of 37%.
Let’s Delve Deep
Macy’s posted adjusted earnings of 27 cents a share that comfortably surpassed the Zacks Consensus Estimate of 14 cents and rose from 21 cents reported in the year-ago period. Earnings gained from solid performance across stores as well as persistent digital growth.
This Cincinnati, OH-based company generated net sales of $5,404 million that surpassed the Zacks Consensus Estimate of $5,379 million and increased 2.3% year over year.
Comparable sales (comps) on an owned plus licensed basis jumped 3.3%, while on an owned basis, comps increased 3.1%. This marked the fourth straight quarter of comps growth for the company. Strategic investments across stores, technology and merchandising are aiding comparable sales growth.
Adjusted EBITDA declined 3.8% to $407 million, while adjusted EBITDA margin contracted 50 basis points to 7.5%.
Macy’s ended the quarter with cash and cash equivalents of $736 million, long-term debt of $5,469 million, and shareholders’ equity of $5,667 million, excluding non-controlling interest of $22 million.
FY18 View
Backed by the confidence in its strategic initiatives and solid execution Macy’s revised its view for fiscal 2018.
The company now anticipates net sales to increase in the range of 0.3-0.7% compared with the prior guidance of flat to up 0.7%. Comps on an owned plus licensed basis are projected to increase 2.3-2.5% increase compared with the previous guidance of 2.1-2.5% growth. However, the company continues to expect comps on an owned basis to be 20-30 basis points lower than comps on an owned plus licensed basis.
Management now envisions adjusted earnings in the range of $4.10-$4.30 per share for fiscal 2018, up from the prior view of $3.95-$4.15. The Zacks Consensus Estimate for the fiscal year is pegged at $4.03, which is likely to witness upward revision in the coming days.
Target Corporation (TGT - Free Report) has a long-term earnings growth rate of 6.7% and a Zacks Rank #2.
Burlington Stores (BURL - Free Report) has a long-term earnings growth rate of 20.8% and carries a Zacks Rank #2.
3 Medical Stocks to Buy Now
The greatest discovery in this century of biology is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating revenue, and cures for a variety of deadly diseases are in the pipeline.
So are big potential profits for early investors. Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it.
Image: Bigstock
Macy's (M) Beats on Q3 Earnings & Sales, Updates Outlook
Macy’s, Inc. (M - Free Report) delivered the sixth straight quarter of positive earnings surprise, when it reported third-quarter fiscal 2018 results. Total sales also came ahead of the consensus mark after missing the same in the preceding quarter. Better-than-expected results prompted management to lift earnings view.
The company highlighted that impressive performance across Macy’s, Bloomingdale’s and Bluemercury brands boosted results. Management hinted that its Growth50 stores initiative is aiding its brick-and-mortar performance. This along with double-digit growth in the digital business bode well. Notably, this Zacks Rank #2 (Buy) stock has rallied 42% year to date, compared with the industry's gain of 37%.
Let’s Delve Deep
Macy’s posted adjusted earnings of 27 cents a share that comfortably surpassed the Zacks Consensus Estimate of 14 cents and rose from 21 cents reported in the year-ago period. Earnings gained from solid performance across stores as well as persistent digital growth.
This Cincinnati, OH-based company generated net sales of $5,404 million that surpassed the Zacks Consensus Estimate of $5,379 million and increased 2.3% year over year.
Comparable sales (comps) on an owned plus licensed basis jumped 3.3%, while on an owned basis, comps increased 3.1%. This marked the fourth straight quarter of comps growth for the company. Strategic investments across stores, technology and merchandising are aiding comparable sales growth.
Adjusted EBITDA declined 3.8% to $407 million, while adjusted EBITDA margin contracted 50 basis points to 7.5%.
Macy's, Inc. Price, Consensus and EPS Surprise
Macy's, Inc. Price, Consensus and EPS Surprise | Macy's, Inc. Quote
Other Financial Aspects
Macy’s ended the quarter with cash and cash equivalents of $736 million, long-term debt of $5,469 million, and shareholders’ equity of $5,667 million, excluding non-controlling interest of $22 million.
FY18 View
Backed by the confidence in its strategic initiatives and solid execution Macy’s revised its view for fiscal 2018.
The company now anticipates net sales to increase in the range of 0.3-0.7% compared with the prior guidance of flat to up 0.7%. Comps on an owned plus licensed basis are projected to increase 2.3-2.5% increase compared with the previous guidance of 2.1-2.5% growth. However, the company continues to expect comps on an owned basis to be 20-30 basis points lower than comps on an owned plus licensed basis.
Management now envisions adjusted earnings in the range of $4.10-$4.30 per share for fiscal 2018, up from the prior view of $3.95-$4.15. The Zacks Consensus Estimate for the fiscal year is pegged at $4.03, which is likely to witness upward revision in the coming days.
Check These 3 Trending Picks
Kohl's Corporation (KSS - Free Report) delivered an average positive earnings surprise of 10% in the trailing four quarters. It has a long-term earnings growth rate of 6.7% and a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Target Corporation (TGT - Free Report) has a long-term earnings growth rate of 6.7% and a Zacks Rank #2.
Burlington Stores (BURL - Free Report) has a long-term earnings growth rate of 20.8% and carries a Zacks Rank #2.
3 Medical Stocks to Buy Now
The greatest discovery in this century of biology is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating revenue, and cures for a variety of deadly diseases are in the pipeline.
So are big potential profits for early investors. Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it.
See them today for free >>